---

---

trial   publishing date : 2021 - 04 - 15   

save search

---

TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple SclerosisWebcast to be held tomorrow, April 16, 2021 at 8:30 AM ET
Published: 2021-04-15 (Crawled : 23:00) - biospace.com/
TGTX | News | $13.99 1.23% 1.29% 3.1M |

Health Technology

| -68.61% | O: 1.3% H: 1.88% C: 1.51%
multiple sclerosis results sclerosis phase 3 trial

---

STAG Industrial To Ring Closing Bell At The New York Stock Exchange
Published: 2021-04-15 (Crawled : 21:00) - prnewswire.com
STAG | $34.38 -1.29% -0.09% 1.1M |

Finance

| -2.38% | O: 0.36% H: 0.2% C: -0.7%
trial

---

Parexel and Veeva Partner to Accelerate Clinical Trials
Published: 2021-04-15 (Crawled : 19:00) - biospace.com/
VEEV | News | $199.54 0.17% -0.77% 720K |

Technology Services

| -25.92% | O: 1.38% H: 1.91% C: 1.4%
clinical trials trial

---

CNH Industrial announces voting results of Annual General Meeting and publication of 2020 Sustainability Report
Published: 2021-04-15 (Crawled : 17:00) - globenewswire.com
CNHI | News | $12.4 0.32% 0.0% 5.2M |

Producer Manufacturing

| -21.22% | O: -0.19% H: 0.06% C: -0.13%
results trial

---

IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors
Published: 2021-04-15 (Crawled : 14:15) - biospace.com/
IDYA | $37.62 -6.35% -6.75% 850K |

Health Technology

| 113.78% | O: -0.05% H: 3.3% C: -0.43%
solid tumors phase 1 trial phase 2 phase 3

---

Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias
Published: 2021-04-15 (Crawled : 14:00) - biospace.com/
SNDX | $20.49 -1.21% -1.47% 1.2M |

Health Technology

| -4.34% | O: -0.05% H: 1.62% C: -3.18%
phase 1 leukemia trial conference phase 2 phase 3

---

BioSpace Global Roundup: Boehringer Ingelheim Launches Weight-Loss Trials for...
Published: 2021-04-15 (Crawled : 14:00) - biospace.com/
ZEAL | $17.59 1.21% -4.21% |

Health Technology

| -45.03% | O: 3.11% H: 0.41% C: -0.53%
space spac trial

---

OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma
Published: 2021-04-15 (Crawled : 14:00) - biospace.com/
ONCS | $0.2772 25.59% 52M |

Health Services

| -94.05% | O: 8.37% H: 0.0% C: -4.36%
phase 2 phase 2b trial

---

BioSpace Global Roundup: Boehringer Ingelheim Launches Weight-Loss Trials for NASH
Published: 2021-04-15 (Crawled : 13:15) - biospace.com/
ZEAL | $17.59 1.21% -4.21% |

Health Technology

| -45.03% | O: 3.11% H: 0.41% C: -0.53%
space spac nash trial

---

US Transdermal Patch Market Size Patch Demand Sales Clinical Trials Opportunity 2026
Published: 2021-04-15 (Crawled : 13:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M |

Manufacturing

| -96.19% | O: 4.02% H: 0.0% C: -11.6%
trial sales clinical trials

---

First Patient Enrolled in PROTECT IV Randomized Controlled Trial of Impella
Published: 2021-04-15 (Crawled : 13:00) - biospace.com/
ABMD | $381.02 0.06% 0.07% |

Health Technology

| 15.25% | O: 0.87% H: 1.79% C: 1.23%
trial enroll

---

Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2021-04-15 (Crawled : 13:00) - biospace.com/
RGLS | $2.22 -5.13% -5.41% 200K |

Health Technology

| 63.24% | O: -0.74% H: 8.89% C: 3.7%
disease treatment phase 1 trial phase 1b kidney phase 2b

---

CSW Industrials Increases Quarterly Dividend by 11%
Published: 2021-04-15 (Crawled : 13:00) - globenewswire.com
CSWI | $233.98 0.67% 0.77% 98K |

Process Industries

| 69.37% | O: 0.58% H: 0.24% C: 0.02%
trial

---

Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir
Published: 2021-04-15 (Crawled : 12:15) - biospace.com/
MRK | $125.23 -0.11% -0.54% 3.4M |

Health Technology

| 64.1% | O: -0.46% H: 1.68% C: 0.8%
iot molnupiravir program

---

Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma
Published: 2021-04-15 (Crawled : 12:15) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M |

Manufacturing

| -96.19% | O: 4.02% H: 0.0% C: -11.6%
phase 1 phase 2 phase 3 glaucoma therapy enroll designation

---

Diamyd Medical contracts global CRO for Phase III trial with the diabetes vaccine Diamyd®
Published: 2021-04-15 (Crawled : 11:00) - prnewswire.com
ICLR | $291.82 -0.07% -0.1% 500K |

Health Technology

| 48.66% | O: 1.5% H: 3.57% C: 2.92%
diabetes contract vaccine trial

---

Gainers vs Losers

58%

42%

Top 10 Gainers

ZCMD | $1.45 5.84% 49.63% 15M |

Commercial Services

AULT | $0.2421 -7.7% 45.23% 16M |

Manufacturing

TPET | $0.3279 -3.56% 28.48% 33M |

n/a

TIRX | $0.8 65.02% 25.95% 410K |

VTNR 4 | $1.31 33.78% 25.82% 220K |

Industrial Services

GDHG | $0.263 21.76% 25.34% 1.3M |

HOLO | $2.95 31.7% 22.49% 37M |

MTNB | $0.19 -1.04% 14.58% 950K |

Health Technology

UMAC | $1.55 0.65% 12.9% 0 |

TAOP | $1.08 13.01% 11.51% 19K |

Technology Services

---

Your saved searches

---